Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Posted on by Cell Biologist

Prof. Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Prof. Zhijie Chang, Tsinghua University, China

Professor Zhijie Chang is a distinguished molecular biologist and tenured professor at the School of Medicine and School of Life Sciences, Tsinghua University, Beijing. His research spans cancer signaling pathways, extracellular vesicle-mediated communication, and stem cell therapy, especially in lung diseases and tumor biology. A seasoned scholar, Dr. Chang earned his Ph.D. in Animal Genetics and Breeding before undertaking postdoctoral training at the University of Alabama at Birmingham. He is currently a respected editor of FEBS Letters and a leader in molecular oncology in China. His recent works highlight the role of CREPT, Smad signaling, and macrophage modulation in cancer and fibrosis. Through decades of academic and translational research, he has significantly advanced our understanding of cell communication in disease contexts. With an extensive publication record in top journals, Dr. Chang remains a leading figure in Asia’s biomedical research landscape.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Contributions in Cell Communication
    Prof. Chang’s research on CREPT, Smad proteins, NF-κB/Nrf2, and BMP signaling has directly advanced the understanding of how intracellular and intercellular communication impacts disease progression, especially in cancer and pulmonary disorders.

  2. High-Impact Publications
    He has numerous peer-reviewed articles in prestigious journals such as Nature Communications, Molecular Cancer, Signal Transduction and Targeted Therapy, and Journal of Biological Chemistry, many of which explore molecular and cellular communication in cancer and tissue repair.

  3. Translational Focus
    His integration of mesenchymal stem cell therapy, extracellular vesicles, and gene therapy reflects a strong translational approach, applying basic science to therapeutic innovations—a critical criterion for this award.

  4. Scientific Leadership and Mentorship
    As a tenured professor at Tsinghua University and editor at FEBS Letters, Prof. Chang is a leader in biomedical research and scientific dissemination, actively contributing to academic growth and mentorship.

⚠️ Areas for Improvement:

  1. More Global Recognition
    While well-known in Chinese biomedical circles and respected internationally through publications, increased involvement in global consortia or leadership in international collaborations would further solidify his global scientific footprint.

  2. Public/Community Science Engagement
    Enhancing visibility through public lectures, science communication platforms, or policy advisory roles could broaden the societal impact of his work.

  3. Data-Sharing and Open Science Practices
    Encouraging or highlighting open-access datasets, repositories, or reproducible workflows would align with best practices in modern cell communication research.

🎓 Education:

Professor Zhijie Chang began his academic journey at Northwestern Agricultural University in Yangling, China, where he earned his B.Sc. (1978–1982) in Animal Science. He then continued at the same institution to obtain a combined M.Sc. and Ph.D. in Animal Genetics and Breeding from 1982 to 1989. His graduate research laid the foundation for his future in molecular biology, signaling studies, and genetics. Seeking international exposure and advanced training, he undertook postdoctoral research from March 1997 to October 1998 at the University of Alabama at Birmingham, USA, in the Department of Pathology. There, he specialized in the BMP signaling pathway, gaining expertise in molecular signaling processes critical to cell communication. This blend of domestic and international education has equipped Dr. Chang with both the technical rigor and global perspective needed to pioneer breakthroughs in biomedical science.

💼 Professional Experience:

Professor Zhijie Chang has held a full professorship at Tsinghua University’s School of Medicine since June 2005, where he investigates cancer-related signaling mechanisms. Before this, he completed postdoctoral research at the University of Alabama at Birmingham, focusing on BMP signaling, which strengthened his understanding of developmental and pathological cell signaling. Over the years, he has built a highly productive research lab, contributed extensively to translational medicine, and trained numerous doctoral and postdoctoral researchers. As an editor of FEBS Letters, he also contributes to scientific publishing and peer-review processes. His roles across academia, research, and editorial boards mark him as a multifaceted scientist whose work bridges laboratory insights and therapeutic applications. His collaborative style and consistent research funding reflect his leadership and innovation in molecular oncology and regenerative medicine.

🏅 Awards and Honors:

Professor Zhijie Chang has been recognized multiple times by the Chinese Cell Biology Society for his high-impact publications. In 2003, he received the First Merit Paper Award for his groundbreaking research on hSef-mediated MAPK signaling inhibition in J. Biol. Chem. In 2005, he earned the Third Merit Paper Award for his study on CHIP-mediated degradation of Smad proteins, published in Mol. Cell. Biol.. These awards underscore his early and sustained contributions to deciphering molecular signaling pathways involved in cell communication, differentiation, and oncogenesis. His recent recognitions include publications in top-tier journals like Nature Communications, Molecular Cancer, and Signal Transduction and Targeted Therapy, indicating the continued relevance and innovation of his work. His role as an editor for FEBS Letters further highlights his stature in the field and dedication to advancing cell biology research at national and international levels.

🔬 Research Focus:

Dr. Zhijie Chang’s research primarily investigates cellular communication in cancer and inflammatory diseases, with a focus on CREPT, Smad proteins, and extracellular vesicles. His work dissects how tumor-derived signals modulate the tumor microenvironment, metastasis, and immune cell behavior. He has made critical discoveries regarding the role of CREPT in chromatin looping and transcriptional regulation, especially in triple-negative breast cancer. In pulmonary fibrosis models, he has shown how umbilical cord-derived mesenchymal stem cells (MSCs) modulate macrophage activity via secreted vesicles. Another major area is his exploration of Smurf1, PDK1–Akt, and JAK/STAT3 signaling axes, targeting them for therapeutic intervention in various cancers. His translational approach integrates gene therapy, stem cell-based treatments, and protein signaling studies, bridging basic and clinical sciences. Through collaborative and interdisciplinary methods, Dr. Chang contributes valuable insights into how cells communicate and respond in disease settings.

📚 Publication Top Notes:

  1. 📘 CREPT is required for the metastasis of triple-negative breast cancer through a co-operational-chromatin loop-based gene regulation

  2. 🧪 Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment

  3. 🧬 Gene Therapy with Enterovirus 3C Protease: A Promising Strategy for Various Solid Tumors

  4. 🌬 Umbilical cord-derived mesenchymal stem cells preferentially modulate macrophages to alleviate pulmonary fibrosis

  5. ⚡ CREPT upregulates the antioxidant genes via activation of NF-κB/Nrf2 in acute liver injury

  6. 🔁 An oncoprotein CREPT functions as a co-factor in MYC-driven transformation and tumor growth

  7. 🎯 Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer

  8. 📤 Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization

  9. 🔋 Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine

  10. 🍄 Lachnochromonin, a fungal metabolite from Lachnum virgineum, inhibits cell growth and promotes apoptosis in tumor cells through JAK/STAT3 signaling

🧾 Conclusion:

Professor Zhijie Chang exhibits a robust and well-established career built on investigating mechanisms of cell signaling, tumor microenvironment dynamics, and intercellular communication. His scientific rigor, translational impact, and leadership in the field of cell communication make him an outstanding candidate for the Research for Cell Communication Award. Addressing some broader outreach and open science practices could further elevate his profile, but his contributions to foundational and applied research in this domain are already exemplary.

Lijuan Deng | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Posted on by Cell Biologist

Mrs. Lijuan Deng | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Mrs. Lijuan Deng , Zhongshan Institute for Drug Discovery , China

Lijuan Deng is a passionate graduate student researcher at the Zhongshan Institute for Drug Discovery in China, specializing in the molecular mechanisms underlying metabolic diseases. Her scientific curiosity centers on gene regulation, signaling pathways, and metabolic dysregulation in disease progression, particularly metabolic-associated fatty liver disease (MASLD). Her translational approach blends experimental models and bioinformatics to bridge basic science and therapeutic innovation. Lijuan has already co-authored a publication in The FASEB Journal, identifying CDKN1A as a key regulator in MASLD. She is also the inventor of a patent-pending technique for nascent RNA labeling in extracellular vesicles. Through collaborations with clinical researchers and a solid foundation in molecular biology techniques, she is positioning herself as a rising talent in cell biology. Her work promises to advance understanding and treatment of metabolic diseases.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Innovative Research: Lijuan Deng has significantly contributed to the understanding of MASLD (Metabolic-Associated Steatotic Liver Disease) by identifying CDKN1A as a key regulatory gene through integrated transcriptomic analysis and experimental validation.

  2. Translational Focus: Her research bridges molecular biology and clinical application, enhancing its impact in drug discovery and disease diagnostics.

  3. Publication Record: She is the first author of a peer-reviewed article published in The FASEB Journal (SCI-indexed), showcasing her ability to conduct and communicate high-quality research.

  4. Patent Innovation: She holds a pending patent for a novel method involving nascent RNA labeling in extracellular vesicles, showing her drive toward technological advancement and biomedical innovation.

  5. Collaborative Approach: Active collaboration with the Department of Endocrinology at Shenzhen Second People’s Hospital reflects strong interdisciplinary and clinical integration.

🧩 Areas for Improvement:

  1. Expanded Publication Portfolio: Increasing the number of peer-reviewed articles will strengthen her academic visibility and impact.

  2. Professional Networking: Engagement in international cell biology societies or conferences and obtaining professional memberships can support broader recognition and growth.

  3. Editorial/Leadership Roles: Participation in editorial boards, review panels, or student leadership roles can enrich her professional development profile.

🎓 Education:

Lijuan Deng is currently pursuing her graduate studies in molecular biology at the Zhongshan Institute for Drug Discovery, where she focuses on translational biomedical research. Her academic foundation includes advanced coursework in biochemistry, molecular genetics, and cellular signaling. Through structured academic training, she has acquired proficiency in modern laboratory methods, including RNA sequencing, qPCR, western blotting, and exosome analysis. Her education emphasizes critical thinking and scientific rigor, enabling her to design experiments, analyze data, and interpret biological outcomes. She regularly participates in academic seminars, journal clubs, and collaborative workshops to refine her scientific acumen. Her thesis research is centered around identifying novel molecular targets in MASLD, a field gaining global relevance. Lijuan’s education is not only shaping her technical capabilities but also nurturing her ambition to contribute to impactful, real-world medical solutions through cell biology research.

💼 Experience:

Lijuan Deng has gained extensive laboratory experience as a graduate student researcher at the Zhongshan Institute for Drug Discovery. Her hands-on work includes both cellular and animal models, with a strong focus on metabolic disease mechanisms. She played a key role in identifying CDKN1A as a potential MASLD progression factor, combining transcriptomic data analysis with molecular validation. Additionally, she has worked on exosome-based biomarker discovery and developed a patent-pending method for nascent RNA labeling. She collaborates with the Department of Endocrinology at Shenzhen Second People’s Hospital, providing a clinical dimension to her work. Though early in her career, her contributions to translational research are already making an impact. She is skilled in molecular biology, gene expression profiling, and therapeutic target screening. Her research experience has been shaped by interdisciplinary collaboration, scientific publications, and the ambition to innovate within the field of molecular cell biology.

🧬 Research Focus:

Lijuan Deng’s research is primarily focused on the molecular underpinnings of metabolic-associated fatty liver disease (MASLD), a key manifestation of metabolic syndrome. She investigates how dysregulated genes, signaling networks, and lipid metabolism contribute to disease initiation and progression. A major highlight of her work is identifying CDKN1A as a potential risk factor in MASLD using integrated bioinformatics and experimental techniques. Additionally, she explores the utility of extracellular vesicles as carriers of diagnostic biomarkers and therapeutic molecules. Her patent-pending work involves a novel method for labeling nascent RNA within exosomes, opening possibilities for tracking dynamic RNA communication in disease contexts. Her research strategy merges molecular biology with disease modeling, aiming to bridge laboratory discoveries with potential therapeutic strategies. Through strong collaborations and a translational research outlook, Lijuan is dedicated to uncovering actionable insights that can inform drug development for complex metabolic disorders.

📚 Publications Top Notes:

  • 🧾 “Identification of CDKN1A as a potential key risk factor in MASLD progression.” – The FASEB Journal, 2025. DOI: 10.1096/fj.202402942R

🧾 Conclusion:

Lijuan Deng stands out as an emerging researcher with strong foundations in molecular cell biology and a clear orientation toward translational science. Her innovative work in MASLD, combined with an SCI publication and a pending patent, make her a highly suitable and promising candidate for the Molecular Cell Biology Award. While she is in the early stages of her career, her achievements thus far indicate substantial potential for future contributions to the field.